Figure 2. Simultaneous deletion of VEGF and p53 in the hematopoietic/endothelial lineage reduces hemangiosarcoma incidence. (A) Kaplan–Meier tumor-free survival curve for Tie2-Cre, p53fl/+, VEGFfl/fl; Tie2-Cre, p53fl/fl, VEGFfl/+, and Tie2-Cre, p53fl/fl, VEGFfl/fl mice. (B) Bar chart comparing tumor spectrum before and after VEGF deletion. Decrease in hemangiosarcoma development is observed in Tie2-Cre, p53fl/fl, VEGFfl/+ mice (n = 12; P ≤ 0.005) and Tie2-Cre, p53fl/fl, VEGFfl/fl mice (n = 11; P ≤ 0.005) vs. Tie2-Cre, p53fl/fl mice (n = 21).